<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sol Schulman, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 15, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin K is a cofactor for the enzymatic conversion of select glutamic acid (Glu) residues in vitamin K-dependent proteins into gamma-carboxyglutamic acid (Gla), which has important functional implications. This process is the target of vitamin K antagonist (VKA) anticoagulants.
        </p>
        <p>
         The functions of Gla within coagulation factors and other proteins are reviewed here, along with synthesis of Gla and the role of vitamin K and vitamin K antagonists.
        </p>
        <p>
         Separate topics discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clotting cascade – (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin K dietary requirements and deficiency – (See
         <a class="medical medical_review" href="/z/d/html/2624.html" rel="external">
          "Overview of vitamin K"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VKA mechanism of action – (See
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3966822896">
         <span class="h1">
          FUNCTIONS OF Gla
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gamma-carboxyglutamic acid (Gla) has primarily been studied in the vitamin K-dependent blood coagulation factors (factors II [prothrombin], VII, IX, and X), proteins that regulate blood clotting (proteins C, S, and Z), and proteins of mineralized tissue (bone Gla protein and matrix Gla protein). Several other proteins that contain Gla domains of unknown function have been identified, including Gas6 and others. (See
         <a class="local">
          'Protein substrates for gamma-carboxylation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2699951816">
         <span class="h2">
          Timeline of discoveries
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin K
         </strong>
         – Vitamin K and its association with blood clotting were initially described in the 1920s and 1930s, following investigation of a hemorrhagic disease of cattle caused by ingestion of spoiled sweet clover [
         <a href="#rid1">
          1
         </a>
         ]. A similar phenomenon was observed in chickens [
         <a href="#rid2">
          2
         </a>
         ]. The vitamin K antagonist (VKA) activity was purified in 1941 [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'VKA inhibition of VKOR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequent studies led to the proposal of a mechanism of vitamin K-mediated enhancement of carboxylase action and regulation of enzymatic vitamin K epoxidase activity by glutamate-containing substrate [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gla and the carboxylase
         </strong>
         – In the 1970s, Gla was discovered in blood clotting proteins and determined to confer metal-binding properties required for membrane-protein interactions of certain clotting factors [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The enzyme activity of the vitamin K-dependent gamma-glutamyl carboxylase was reported in 1975, and the
         <em>
          GGCX
         </em>
         gene was published in 1991 [
         <a href="#rid10">
          10,11
         </a>
         ]. Subsequent studies characterized the structure of the carboxylase enzyme and features of vitamin K-dependent proteins including the propeptide and gamma-carboxylation recognition site [
         <a href="#rid10">
          10-16
         </a>
         ]. (See
         <a class="local">
          'Gamma-glutamyl carboxylase enzyme'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This carboxylase activity is found in essentially all mammalian tissues, and its reaction product, Gla, has been observed in both vertebrates and invertebrates [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VKOR
         </strong>
         – The vitamin K recycling enzyme (vitamin K epoxide reductase [VKOR]), target of the VKA anticoagulants, and the
         <em>
          VKORC1
         </em>
         gene, were published in 2004 [
         <a href="#rid18">
          18,19
         </a>
         ]. Subsequent studies characterized the enzyme structure and mechanism of action. [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FSP1
         </strong>
         – In 2022 and 2023, the FSP1 protein, encoded by the
         <em>
          FSP1
         </em>
         gene, was identified as the primary warfarin-independent vitamin K reductase, enabling rescue of VKA toxicity and suppressing ferroptosis [
         <a href="#rid22">
          22,23
         </a>
         ]. (See
         <a class="local">
          'Ferroptosis suppressor 1 (FSP1) and other enzymes that can reduce vitamin K'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2010703020">
         <span class="h2">
          Function of Gla in clotting proteins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clotting proteins circulate in an inactive form and become activated at sites of hemostasis. The main function of Gla domains in the vitamin K-dependent clotting proteins is to facilitate their localization to phospholipid membranes, which is essential to turning on their procoagulant activity. (See
         <a class="local">
          'Protein substrates for gamma-carboxylation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Multicomponent complexes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H942190100">
         <span class="h3">
          Procoagulant factors (factors II, VII, IX, and X)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factor II [prothrombin] is the precursor to thrombin. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Thrombin generation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factors VII, IX, and X contribute to thrombin generation. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Clotting cascade and propagation of the clot'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2540926111">
         <span class="h3">
          Natural anticoagulants (proteins C, S, and Z)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activated protein C (aPC) inactivates coagulation factors Va and VIIIa. Protein S enhances aPC activity. (See
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Biology of protein C'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">
          "Protein S deficiency", section on 'Biology of protein S'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein Z and a protein Z-dependent protease inhibitor (ZPI) appear to serve as cofactors for the inhibition of activated factors X and XI [
         <a href="#rid24">
          24-26
         </a>
         ]. ZPI inhibition of factor Xa bound to phospholipid membranes, but not in solution, is dependent upon an interaction between the Gla domains of protein Z and factor Xa [
         <a href="#rid27">
          27
         </a>
         ]. Deficiencies of protein Z or ZPI, as with deficiencies of proteins C and S, might therefore result in a prothrombotic state or might rebalance bleeding phenotypes in hereditary hemostatic disorders [
         <a href="#rid28">
          28-34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2023272102">
         <span class="h3">
          Phospholipid membrane binding
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vitamin K-dependent clotting proteins contain 10 to 12 Gla residues in the Gla domain, which is located within the first 40 residues of the N-termini of the mature proteins. The surface of the Gla domain, in association with the adjacent aromatic amino acid stack domain, functions as a membrane-binding component of these proteins.
        </p>
        <p>
         The following observations emphasize the importance of phospholipid binding to the function of these clotting proteins:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         causes vitamin K-dependent proteins to be undercarboxylated, having Glu residues at some or all of the positions that are usually carboxylated to Gla. These proteins are either biologically inert or are misfolded in the endoplasmic reticulum and degraded by quality control pathways (protein C) or otherwise not secreted (protein S). In patients treated with warfarin, circulating coagulant activity correlates closely with the quantity of fully carboxylated proteins remaining in the circulation [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'VKA inhibition of VKOR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gla differs from aspartic acid and glutamic acid (Glu) in containing two carboxyl groups in its side chain. This bivalency enables the formation of the calcium-carboxylate network that stabilizes the Gla domains and, in the vitamin K-dependent clotting proteins, allows expression of the phospholipid binding site. In most cases, neither aspartic acid nor Glu, nor a mutated form of the protein that cannot be gamma-carboxylated, will substitute for the function of Gla, emphasizing the importance of both carboxyl groups on a single amino acid [
         <a href="#rid36">
          36-39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Structural analysis of Gla-containing vitamin K-dependent clotting proteins and regulators show that the Gla domain is highly structured and share nearly identical calcium binding sites in the internal core [
         <a href="#rid40">
          40-43
         </a>
         ]. Many of the Gla side chains point inward to a linear array of internal calcium ions, several of which are completely sequestered inside the core of the Gla domain [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Gla domains bind specifically to membrane phosphatidylserine. The structural basis for this comes from crystallographic structure of the lysophosphatidylserine binding site in the bovine prothrombin Gla domain, which demonstrated that the serine head group binds Gla domain-bound calcium ions and Gla residues 17 and 21, which are fixed elements of the Gla domain fold [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         An x-ray structure had shown unexpected exposure of three hydrophobic residues on the surface of these proteins, suggesting a potential role for these residues in membrane interaction [
         <a href="#rid16">
          16
         </a>
         ]. Site-specific mutagenesis of homologous residues in protein C interfered with membrane-binding properties, but mutation of other hydrophobic residues did not perturb membrane binding significantly [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1901247835">
         <span class="h3">
          Calcium-induced conformational change
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gla domains provide a unique mechanism for protein-phospholipid membrane interaction in the presence of calcium. With the addition of calcium ions, the vitamin K-dependent clotting proteins undergo a structural transition that leads to exposure of a phospholipid binding site. Calcium-induced exposure of hydrophobic amino acids in the Gla domain is critical for membrane binding [
         <a href="#rid46">
          46
         </a>
         ]. Direct comparison of the structures of the calcium-stabilized form of factor IX, which binds to membranes, and the magnesium-stabilized form of factor IX, which does not, implicated residues 1 to 11 that form a loop in the Gla domain [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Correlation of membrane-binding properties of the vitamin K-dependent proteins with homology considerations suggests a possible alternative membrane contact site that involves residues 11, 33, and 34 [
         <a href="#rid48">
          48
         </a>
         ]. A molecular dynamics simulation study of anionic phospholipid binding to the Gla domain of bovine fragment 1 in the presence of calcium ions also suggests a phosphatidylserine binding site with the head group bound by a Gla-bound calcium ion, Gla 30 and Lys 11 [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3930069121">
         <span class="h2">
          Function of Gla in bone, connective tissue, and vascular proteins
         </span>
         <span class="headingEndMark">
          —
         </span>
         The function of Gla-containing proteins in mineralized tissue, including osteocalcin and matrix Gla protein, is less well defined than for the clotting proteins. Insights from experimental animal models have suggested the following possible functions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone remodeling
         </strong>
         – Osteocalcin-deficient mice are characterized by increased bone formation, including higher bone mass and bones of improved functional quality [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">
          "Normal skeletal development and regulation of bone formation and resorption"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limiting calcification of extraosseous tissues
         </strong>
         – Matrix Gla protein-deficient mice suffer from spontaneous and ultimately fatal calcification of arteries and cartilage [
         <a href="#rid51">
          51
         </a>
         ], suggesting that one of the functions of this protein is to control and limit extraosseous calcification. Decreased carboxylation of matrix Gla protein following
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         treatment causes rapid arterial and aortic valve calcification in rats and mice [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A similar phenotype has been observed in humans with Keutel syndrome, which is caused by pathogenic variants in the
         <em>
          BGLAP
         </em>
         gene, which encodes matrix Gla protein and is characterized by abnormal cartilage calcification [
         <a href="#rid54">
          54
         </a>
         ]. The Gla residues in matrix Gla protein prevent osteogenic differentiation and calcification via binding and inhibition of bone morphogenetic protein-4, as well as via binding to vascular smooth muscle cell-derived vesicles [
         <a href="#rid55">
          55,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A Gla-rich protein (GRP) of unknown function is expressed in chondrocytes, chondroblasts, osteocytes and osteoblasts; in animals the highest levels are found in bone and cartilage [
         <a href="#rid57">
          57
         </a>
         ]. GRP contains the highest Gla content of any known protein (16 of 74 residues) and is not homologous to any other known Gla-containing proteins. It was originally identified in the calcified cartilage of the Adriatic sturgeon and has orthologs in all vertebrates [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         There is no evidence to support vitamin K administration in patients with osteoporosis or other interventions in patients receiving vitamin K antagonists (VKAs). The relationship of VKA use and bone health is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">
          "Drugs that affect bone metabolism", section on 'Anticoagulants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Therapies not recommended'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3635742487">
         <span class="h2">
          Gla proteins of unknown function
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gas6
         </strong>
         – Gas6 (growth-arrest-specific gene 6) has marked sequence homology in the Gla domain to the vitamin K-dependent blood coagulation and regulatory proteins, in particular protein S [
         <a href="#rid58">
          58
         </a>
         ]. Gas6 is released from and potentiates the growth of vascular smooth muscle cells. When synthesized in the presence of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and therefore lacking Gla, Gas6 demonstrates no thrombin-inducible growth potentiating activity or receptor binding ability [
         <a href="#rid59">
          59
         </a>
         ]. In contrast, Gas6 lacking the entire Gla domain is a functional growth factor. This observation suggests that the Gla domain may be a negative regulator of the structure of a growth factor domain located elsewhere on the molecule.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin K-dependent single-pass integral membrane proteins
         </strong>
         – This family of four proteins was identified by searching a database with a consensus sequence derived from analysis of known Gla domains. They all contain the PPXY motif involved in diverse cellular functions. There are two potential subclasses based on their gene organization and protein sequence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          P
         </strong>
         roline
         <strong>
          r
         </strong>
         ich
         <strong>
          G
         </strong>
         la
         <strong>
          p
         </strong>
         roteins PRGP1 and PRGP2 [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T
         </strong>
         rans
         <strong>
          m
         </strong>
         embrane
         <strong>
          G
         </strong>
         la proteins TMG3 and TMG4 [
         <a href="#rid61">
          61
         </a>
         ]. The gene for TMG4 is one of those deleted in the 11p14-p12 chromosome region deletion associated with WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, and Range of developmental delays) and falls into the linkage region of 11p13-p12 as an autism candidate gene [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16660.html" rel="external">
          "Microdeletion syndromes (chromosomes 1 to 11)", section on '11p13 deletion syndrome (WAGR syndrome)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endoplasmic reticulum Gla protein
         </strong>
         – This gamma-carboxylated calcium-binding protein was identified in the endoplasmic reticulum of pancreatic beta-cells [
         <a href="#rid63">
          63
         </a>
         ]. Gamma-carboxylation of regulates calcium homeostasis in beta-cells and is critical for their capacity to adapt insulin secretion to metabolic needs. Glucose upregulates carboxylase activity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3725003805">
         <span class="h1">
          Gla SYNTHESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gamma carboxyglutamic acid (Gla) is an alternative amino acid created by modification of the amino acid glutamic acid (Glu, also called glutamate).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gamma-glutamyl carboxylase (GGCX)
         </strong>
         – GGCX is the enzyme that catalyzes the conversion of Glu to Gla. (See
         <a class="local">
          'Gamma-glutamyl carboxylase enzyme'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin K
         </strong>
         – Vitamin K is a cofactor in the carboxylation reaction. (See
         <a class="local">
          'Vitamin K requirement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4137432767">
         <span class="h2">
          Protein substrates for gamma-carboxylation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following proteins require gamma carboxylation of glutamic acid residues to produce gamma-carboxyglutamic acid (Gla):
        </p>
        <p>
         Gla residues in the vitamin K-dependent clotting factors and natural anticoagulants facilitate membrane binding. (See
         <a class="local">
          'Function of Gla in clotting proteins'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulation factors
         </strong>
         – These are the vitamin K-dependent clotting factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor II (prothrombin)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor VII
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor IX
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor X
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proteins that regulate coagulation
         </strong>
         – These are natural anticoagulants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protein C
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protein S
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protein Z
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone and matrix proteins
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osteocalcin (also called bone Gla protein)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Matrix Gla protein
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gla-rich protein
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These proteins may function in bone remodeling or preventing calcification of extraosseous tissues and vasculature. (See
         <a class="local">
          'Function of Gla in bone, connective tissue, and vascular proteins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Functions of additional Gla proteins are unclear. (See
         <a class="local">
          'Gla proteins of unknown function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gas6
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vitamin K-dependent single-pass integral membrane proteins
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endoplasmic reticulum Gla protein
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carboxylase
         </strong>
         – The GGCX enzyme itself has Glu residues in a region of sequence homology with the region of matrix Gla protein containing the gamma-carboxylation recognition site [
         <a href="#rid64">
          64
         </a>
         ]. Under some conditions, the carboxylase can become carboxylated, although the role of Gla in this enzyme remains to be determined [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="local">
          'Gamma-glutamyl carboxylase enzyme'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cone snail conotoxin
         </strong>
         – Only one invertebrate, the cone snail, has been found to contain Gla in toxins used to sting prey (conotoxins); many of the conotoxins are channel blockers [
         <a href="#rid66">
          66-69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6591.html" rel="external">
          "Marine envenomations from corals, sea urchins, fish, or stingrays", section on 'Cone snail'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H184570797">
         <span class="h2">
          Gamma-carboxylation recognition site
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clotting factors and regulatory proteins
         </strong>
         – The propeptide region of the vitamin K-dependent clotting proteins (factors II [prothrombin], VII, IX, and X) and the regulatory proteins (proteins S, C, and Z) functions as a recognition sequence, binding the carboxylase to its substrate on the adjacent glutamic acid rich domain (referred to as a "Gla domain") [
         <a href="#rid12">
          12,13
         </a>
         ]. It also stimulates gamma-glutamyl carboxylation [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone and matrix Gla proteins
         </strong>
         – For the matrix Gla protein, the gamma-carboxylation recognition site resides within the mature protein sequence itself in matrix Gla protein [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The propeptide of osteocalcin (bone Gla protein) is unable to support carboxylation of blood coagulation factors [
         <a href="#rid73">
          73
         </a>
         ]; this suggests that the previously established determinants of clotting factor carboxylation may not apply to all Gla proteins.
        </p>
        <p>
        </p>
        <p>
         The vitamin K-dependent carboxylase binds directly to the amino acids of the propeptide recognition site [
         <a href="#rid74">
          74
         </a>
         ]. Although no consensus sequence prevails in the carboxylation recognition sites, these sites are best defined by a Z-F-Z-X-X-X-X-A motif, where Z is an aliphatic hydrophobic residue (isoleucine, valine, or leucine), F is phenylalanine, A is alanine, and X is any amino acid. Phenylalanine at residue 16 is preferred in carboxylase substrates, but leucine, valine, and lysine at this position also support carboxylation [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Evidence from point mutations illustrates how the carboxylation recognition site in the propeptide region of vitamin K-dependent clotting factors is required for gamma carboxylation [
         <a href="#rid12">
          12,13,76-81
         </a>
         ].
        </p>
        <p>
         This carboxylation site region in clotting factor precursors likely docks with the membrane-bound carboxylase, bringing the active site of the carboxylase in proximity to the substrate Glu residues on the clotting factor precursor.
        </p>
        <p>
         A protein will likely undergo gamma-carboxylation if it meets the following criteria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It has a gamma-carboxylation recognition site that interacts with the carboxylase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glu residues are present within 40 residues of the recognition site
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cell contains reduced vitamin K
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cell has the carboxylase enzyme associated with the rough endoplasmic reticulum (RER), and the protein is routed through the RER during biosynthesis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1142077205">
         <span class="h2">
          Gamma-glutamyl carboxylase enzyme
         </span>
        </p>
        <p class="headingAnchor" id="H987441075">
         <span class="h3">
          GGCX enzyme function
         </span>
         <span class="headingEndMark">
          —
         </span>
         The gamma-glutamyl carboxylase (GGCX, also called the vitamin K-dependent carboxylase) is an integral membrane protein that converts glutamic acid (Glu) amino acid residues to Gla  (
         <a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid10">
          10,82
         </a>
         ].
        </p>
        <p>
         Cofactors required for the carboxylation reaction include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carbon dioxide.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular oxygen.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin K in the
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         form. (See
         <a class="local">
          'Vitamin K requirement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The enzyme catalyzes two coupled reactions [
         <a href="#rid4">
          4,83,84
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It promotes the formation of Gla on the Glu residues.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It promotes the formation of the highly reactive alkoxide, which then collapses into the epoxide form of vitamin K.
        </p>
        <p>
        </p>
        <p>
         The enzyme has the following features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A carboxylase active site.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An epoxidase active site.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A propeptide binding site (shares sequence similarity with the propeptide of the carboxylase substrate) [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A propeptide binding site that stimulates carboxylase and epoxidase activity.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A glutamate binding site [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A vitamin K binding site.
        </p>
        <p>
        </p>
        <p>
         The human carboxylase gene,
         <em>
          GGCX
         </em>
         , is a 15-exon gene located on chromosome 2p12 [
         <a href="#rid87">
          87
         </a>
         ]. Variants in
         <em>
          GGCX
         </em>
         can cause a bleeding disorder due to lack of vitamin K-dependent clotting factors. (See
         <a class="local">
          'Genetic deficiency of GGCX (vitamin K-dependent clotting factor deficiency type I)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3635969569">
         <span class="h3">
          Intracellular localization
         </span>
         <span class="headingEndMark">
          —
         </span>
         GGCX is an integral membrane protein localized to the endoplasmic reticulum and Golgi apparatus. Immunofluorescence studies using anti-GGCX antibodies confirm the carboxylase resides in these organelles.
        </p>
        <p>
         Studies in Chinese hamster ovary cells expressing prothrombin showed that uncarboxylated pro-prothrombin is completely gamma-carboxylated in the endoplasmic reticulum [
         <a href="#rid88">
          88
         </a>
         ]. The carboxylated pro-prothrombin leaves the endoplasmic reticulum intact and is further processed in the Golgi apparatus to remove the propeptide to create prothrombin. (See
         <a class="local">
          'Protein substrates for gamma-carboxylation'
         </a>
         above.)
        </p>
        <p>
         Many substrates of GGCX are extracellular proteins (clotting factors and natural anticoagulants).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin and the other gamma-carboxylated extracellular vitamin K-dependent proteins bind to negatively charged phospholipids in the presence of calcium ions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fully carboxylated pro-factor IX does not bind to membranes in the presence of calcium ions, whereas mature factor IX does [
         <a href="#rid89">
          89
         </a>
         ]. Thus, the propeptide attached to factor IX appears to prevent proper folding of the Gla domain, expression of the phospholipid binding site, and the interaction of pro-factor IX with membranes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3921814906">
         <span class="h1">
          VITAMIN K REQUIREMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2699732268">
         <span class="h2">
          Reduced vitamin K (KH2) is the cofactor for GGCX
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin K in the reduced/
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         form (vitamin KH2) is a cofactor for the gamma glutamyl carboxylase (GGCX) enzyme. GGCX is the only enzyme that requires vitamin K.
        </p>
        <p>
         The mechanism by which vitamin K participates as a cofactor for the GGCX enzyme is incompletely understood. An attractive hypothesis is that an activated form of vitamin K extracts a hydrogen atom from the gamma carbon of Glu residues on specific proteins (see
         <a class="local">
          'Protein substrates for gamma-carboxylation'
         </a>
         above), in a reaction that converts the vitamin K to vitamin K epoxide.
        </p>
        <p>
         Carbon dioxide is subsequently added to the gamma-carbon of Glu by the gamma-glutamyl carboxylase to form Gla  (
         <a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid90">
          90
         </a>
         ]. For each molecule of Gla generated, one molecule of vitamin K epoxide is also formed [
         <a href="#rid84">
          84,91
         </a>
         ].
        </p>
        <p>
         A "base strength amplification mechanism" has been proposed to explain the conversion of the weak base form of vitamin K (vitamin KH2) into an oxygenated intermediate (the alkoxide) of sufficient basicity to abstract a hydrogen from the gamma-carbon of Glu  (
         <a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         It was initially proposed that a free cysteine in GGCX was responsible for deprotonation of vitamin KH2, a hypothesis that is supported by numerous publications [
         <a href="#rid83">
          83,92-101
         </a>
         ]. However, other studies question the role of a free cysteine residue in carboxylation and implicate two lysine residues in the gamma-glutamyl carboxylase as important for catalysis [
         <a href="#rid102">
          102,103
         </a>
         ].
        </p>
        <p>
         The short-lived highly reactive alkoxide is potentially toxic, and it would be undesirable for it to be generated in the absence of Glu residues. Evidence indicates that no highly reactive vitamin K intermediate is generated by GGCX until a carboxylase substrate is bound to the enzyme and converts its vitamin K epoxidase function to an active state [
         <a href="#rid4">
          4
         </a>
         ]. The epoxide is then recycled back to vitamin KH2 via a vitamin K epoxide reductase (VKOR). (See
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1942790320">
         <span class="h2">
          Vitamin K recycling by VKOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin K can occupy three distinct redox states:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fully oxidized (two disulfides): vitamin K epoxide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partially oxidized (one disulfide): vitamin K quinone
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced (no disulfides): vitamin K
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         (KH2)
        </p>
        <p>
        </p>
        <p>
         Only a small fraction (5.6 percent) of vitamin K is in a fully reduced (active cofactor) state, with the remainder split almost equally between partially oxidized and fully oxidized [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         Vitamin K
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         (vitamin KH2), the most reduced form of vitamin K, is the active cofactor for the gamma-glutamyl carboxylase. During the conversion of Glu to Gla, vitamin KH2 is oxidized to vitamin K epoxide, the most oxidized form of vitamin K [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="local">
          'Gla synthesis'
         </a>
         above.)
        </p>
        <p>
         Gamma carboxylation causes oxidation of vitamin K. The vitamin must be recycled from the inactive (oxidized) to the active (reduced) form of the cofactor after every gamma carboxylation reaction. (See
         <a class="local">
          'GGCX enzyme function'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VKOR
         </strong>
         – The enzyme vitamin K epoxide reductase (VKOR) catalyzes the sequential reduction of vitamin K epoxide to vitamin K quinone (the naturally occurring form of the vitamin) and then further to vitamin KH2, completing the reductive arm of the vitamin K cycle. These reductions are both inhibited by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and other VKAs. (See
         <a class="local">
          'VKA inhibition of VKOR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         VKOR is effective at low concentrations of vitamin K epoxide and vitamin K quinone and is the physiologically important enzyme for recycling vitamin K [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         VKOR is a 163 amino acid protein encoded by the
         <em>
          VKORC1
         </em>
         gene, located on chromosome 16 [
         <a href="#rid18">
          18,19
         </a>
         ]. It is most highly expressed in the liver (the site of vitamin K-dependent clotting factor production) and is also detected in other tissues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sequence features
         </strong>
         – Alignment of functional VKORs reveals five absolutely conserved residues across all species, including two pairs of cysteine residues (C43 and C51, C132 and C135) and a serine (S57). The C132 and C135 cysteine pair contributes a canonical CXXC motif integral to many cellular redox reactions [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Three-dimensional structure
         </strong>
         – Crystal structures of VKOR and its homologues in other species demonstrate a shared structure in which four transmembrane segments surround a central vitamin K molecule with its redox active quinone ring oriented to the C132-X-X-C135 motif [
         <a href="#rid20">
          20,109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An extracellular loop between transmembrane segments one and two forms a cap over the quinone binding pocket and contains the second pair of conserved cysteines (C43 and C51) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vitamin K epoxide and quinone bind preferentially to the fully reduced and partly oxidized states, with covalent or near covalent interaction between the C135 thiolate that enables electron transfer to vitamin K [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Source of reducing equivalents
         </strong>
         – The source of reducing equivalents for VKOR is of great interest. Early in vitro studies used reducing agents such as dithiothreitol (DTT), which can directly reduce the active site cysteines. Lipoic acid and most dithiols show some activity in vitro [
         <a href="#rid110">
          110
         </a>
         ]. Glutathione is an important redox buffer in the endoplasmic reticulum [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies of bacterial and plant VKOR homologs that catalyze disulfide bond formation in secreted proteins may shed light on the mechanism of VKOR activity [
         <a href="#rid109">
          109,112
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bacterial VKOR homologs that are naturally fused to an extracellular (periplasmic) thioredoxin-like domain containing a CXXC motif as the redox partner have been crystallized, and the crystal structure of the complex in an arrested state of electron transfer between the thioredoxin-like domain and the VKOR homolog has suggested an electron transfer pathway that could apply to other VKOR homologs [
         <a href="#rid109">
          109,112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newly synthesized proteins in the periplasm reduce the CXXC motif of a thioredoxin-like protein, which in turn reduces the conserved disulfide bridge in the extracellular loop of VKOR; the loop cysteines then reduce the conserved CXXC motif of VKOR and, finally, the disulfide in this CXXC motif is reestablished by reduction of the quinone [
         <a href="#rid109">
          109
         </a>
         ]. Mammalian VKOR likely functions similarly as a parallel or redundant system to catalyze oxidative protein folding in the endoplasmic reticulum [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thioredoxin domain containing proteins from bacteria can also support mammalian VKOR-catalyzed reduction of vitamin K epoxide or quinone, and endoplasmic reticulum anchored thioredoxin-like protein TMX forms an identical mixed-disulfide intermediate with human VKOR [
         <a href="#rid21">
          21,114
         </a>
         ]. The extent to which these mechanisms contribute to redox reactions relative to glutathione in vivo remains to be determined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VKOR-like protein
         </strong>
         – VKOR-like protein is a distinct protein encoded by the
         <em>
          VKORC1L1
         </em>
         gene on chromosome 7. This enzyme also catalyzes reduction of vitamin K epoxide and vitamin K quinone to vitamin KH2. It shares all of the essential catalytic residues with VKOR and based on structural studies, it appears to adopt the same overall three-dimensional configuration. It is expressed at low levels across tissues but not enriched in liver, which may explain its inability to compensate for VKOR deficiency. (See
         <a class="local">
          'Genetic deficiency of VKOR (vitamin K-dependent clotting factor deficiency type II)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         VKOR-like protein may significantly contribute to the gamma-carboxylation of extrahepatic vitamin K-dependent proteins with roles beyond coagulation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2715530256">
         <span class="h2">
          Ferroptosis suppressor 1 (FSP1) and other enzymes that can reduce vitamin K
         </span>
         <span class="headingEndMark">
          —
         </span>
         VKOR and VKOR-like protein are the only enzymes known to reduce vitamin K epoxide, but other enzymes are able to reduce vitamin K quinone to the
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         form. These include NQO1 (DT-diaphorase), an NAD(P)H dehydrogenase, and the warfarin-independent, NAD(P)H-dependent vitamin K-reductase encoded by
         <em>
          FSP1
         </em>
         [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         These enzymes, particularly FSP1, enable excess vitamin K to restore gamma-carboxylation in the setting of VKA excess. (See
         <a class="local">
          'Rescue of VKA toxicity by vitamin K'
         </a>
         below.)
        </p>
        <p>
         Ferroptosis is a form of cell death due to iron-induced lipid peroxidation that has been implicated in several neurodegenerative disorders, cancer, and ischemia-reperfusion injury. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Iron and the brain'
         </a>
         .)
        </p>
        <p>
         The ferroptosis suppressor protein FSP1 also acts as a vitamin K reductase, although it cannot reverse all steps of vitamin K antagonist (VKA) activity. (See
         <a class="local">
          'Rescue of VKA toxicity by vitamin K'
         </a>
         below.)
        </p>
        <p>
         One or more additional warfarin-independent vitamin K reductases have yet to be identified [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2746223340">
         <span class="h2">
          Vitamin K antagonist (VKA) mechanisms of action
         </span>
        </p>
        <p class="headingAnchor" id="H2385430944">
         <span class="h3">
          VKA inhibition of VKOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         and other vitamin K antagonist (VKA) anticoagulants block the vitamin K epoxide reductase (VKOR), preventing vitamin K recycling. This in turn produces nonfunctional vitamin K-dependent clotting factors. (See
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         shares a common ring structure with vitamin K.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         and other VKAs bind to many of the same key residues of VKOR as vitamin K and induce the same conformational changes required for the VKOR catalytic cycle [
         <a href="#rid20">
          20
         </a>
         ]. This results in insufficient generation of vitamin K
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         to support full carboxylation and therefore full function of the vitamin K-dependent proteins of blood coagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         preferentially binds to the fully oxidized (two disulfides) and partially oxidized (one disulfide) states of VKOR [
         <a href="#rid115">
          115
         </a>
         ]. Warfarin binding triggers closure of the cap, sealing VKOR in the closed state [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin K epoxide is not detectable in normal plasma, even after a pharmacologic dose of 10 mg of vitamin K [
         <a href="#rid116">
          116
         </a>
         ]. However, it is measurable following the administration of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         [
         <a href="#rid117">
          117,118
         </a>
         ]. The finding in warfarin-treated patients of a significant positive correlation between the degree of anticoagulation and plasma vitamin K epoxide concentrations suggests that this mechanism reflects the pharmacodynamic activity of warfarin in anticoagulated patients [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H237060439">
         <span class="h3">
          Rescue of VKA toxicity by vitamin K
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin K is a logical, widely used, and effective antidote to VKA overdose [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Vitamin K dose, route, formulation'
         </a>
         .)
        </p>
        <p>
         Because the effect is not immediate, individuals with bleeding or requiring emergency surgery require a source of pre-formed vitamin K-dependent clotting factors. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of bleeding'
         </a>
         .)
        </p>
        <p>
         The bypass mechanism by which vitamin K reverses
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         anticoagulation may be partly attributable to the NAD(P)H-dependent reductase NQO1 (DT-diaphorase) [
         <a href="#rid121">
          121
         </a>
         ]; however, this enzyme requires high concentrations of vitamin K and probably does not play a major role at physiologic tissue concentrations of vitamin K [
         <a href="#rid106">
          106
         </a>
         ]. NQO1-deficient mice treated with warfarin can be rescued with vitamin K, suggesting this is not the essential warfarin-independent vitamin K reductase [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Major insights emerge from the discovery that the NAD(P)H quinone oxidoreductase ferroptosis suppressor protein 1 (FSP1) is an efficient vitamin K reductase [
         <a href="#rid22">
          22,23
         </a>
         ]. (See
         <a class="local">
          'Ferroptosis suppressor 1 (FSP1) and other enzymes that can reduce vitamin K'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FSP1 is not sensitive to inhibition by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , and the prolonged prothrombin time (PT) in warfarin-treated FSP1-deficient mice is not rescued by administration of high dose vitamin K [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FSP1, therefore, acts parallel to VKOR and catalyzes the major warfarin-resistant pathway enabling reduction of vitamin K quinone to the
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         form required for gamma-carboxylation. FSP1 is unable to reduce vitamin K epoxide to enable vitamin K recycling, but it provides an essential mechanism to bypass VKA toxicity and preserve blood coagulation [
         <a href="#rid22">
          22,23
         </a>
         ]. This is an important observation that explains why high dose vitamin K can rescue or reverse
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         overdose. (See
         <a class="local">
          'Poisoning by rodenticide superwarfarins'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1945492390">
         <span class="h1">
          CLINICAL RELEVANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Deficiency of vitamin K-dependent clotting factors due to pathogenic variants affecting the gamma-glutamyl carboxylase enzyme (
         <em>
          GGCX
         </em>
         gene) or the vitamin K recycling enzyme (
         <em>
          VKOR
         </em>
         gene) cause a heritable bleeding disorder with reduced factor activity levels and prolongation of the prothrombin time (PT) and activated partial thromboplastin time (aPTT). (See
         <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">
          "Rare inherited coagulation disorders", section on 'Multiple vitamin K-dependent factor deficiencies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1441104948">
         <span class="h2">
          Pathogenic variants in
          <i>
           GGCX
          </i>
         </span>
        </p>
        <p class="headingAnchor" id="H4072900419">
         <span class="h3">
          Genetic deficiency of GGCX (vitamin K-dependent clotting factor deficiency type I)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants affecting the gamma-glutamyl carboxylase gene (
         <em>
          GGCX
         </em>
         ) have been described in a number of kindreds with vitamin K-dependent clotting factor deficiency [VKDCFD] type I, with deficiency of all vitamin K-dependent coagulation factors and a heritable bleeding disorder [
         <a href="#rid123">
          123-125
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">
          "Rare inherited coagulation disorders", section on 'Multiple vitamin K-dependent factor deficiencies'
         </a>
         .)
        </p>
        <p>
         A similar disorder has been found in the Devon Rex cat [
         <a href="#rid126">
          126
         </a>
         ]. Mice carrying a null mutation of the carboxylase gene die at birth of massive intraabdominal hemorrhage [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         In most of the affected humans and in cats, activity of the vitamin K-dependent coagulation factors can be normalized by vitamin K supplementation [
         <a href="#rid126">
          126,128-130
         </a>
         ]. This normalization of activity is possible because the effect of most of the reported pathogenic variants is to weaken the binding of vitamin K to the enzyme. As basal vitamin K concentrations are below the Km of the carboxylase for vitamin K
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         , increasing the concentration of vitamin K raises the levels of the vitamin K-dependent coagulation factors.
        </p>
        <p class="headingAnchor" id="H204223334">
         <span class="h3">
          Syndromes with aberrant calcification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some pathogenic variants in
         <em>
          GGCX
         </em>
         cause aberrant calcification in addition to a mild bleeding disorder, consistent with a role for the carboxylase in preventing calcification of the vasculature [
         <a href="#rid131">
          131-134
         </a>
         ]. (See
         <a class="local">
          'Function of Gla in bone, connective tissue, and vascular proteins'
         </a>
         above.)
        </p>
        <p>
         Patients with a pseudoxanthoma elasticum-like syndrome may have excessive skin folding. Skin biopsies indicate disruption of elastin fibers, abundant calcification, and decreased matrix Gla protein carboxylation. (See
         <a class="medical medical_review" href="/z/d/html/15468.html" rel="external">
          "Pseudoxanthoma elasticum"
         </a>
         .)
        </p>
        <p>
         Most of the variants causing these diseases are in uncharacterized regions of GGCX. (See
         <a class="local">
          'GGCX enzyme function'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H476266954">
         <span class="h2">
          Pathogenic variants in VKORC1
         </span>
        </p>
        <p class="headingAnchor" id="H165299500">
         <span class="h3">
          Genetic deficiency of VKOR (vitamin K-dependent clotting factor deficiency type II)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vitamin K-dependent clotting factor deficiency (VKDCFD) type II is a rare autosomal recessive disorder caused by loss-of-function variants in the
         <em>
          VKORC1
         </em>
         gene, which encodes the vitamin K reducing enzyme vitamin K epoxide reductase (VKOR) [
         <a href="#rid128">
          128,135-137
         </a>
         ]. (See
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">
          "Rare inherited coagulation disorders", section on 'Multiple vitamin K-dependent factor deficiencies'
         </a>
         .)
        </p>
        <p>
         All known cases VKDCFD type II are caused by an Arg98Trp substitution that disrupts endoplasmic reticulum localization of VKOR and leads to its premature degradation [
         <a href="#rid138">
          138
         </a>
         ]. Many patients present with perinatal intracranial hemorrhage or mucosal or soft tissue bleeding in childhood, but rare individuals do not come to clinical attention until adulthood [
         <a href="#rid135">
          135,139
         </a>
         ].
        </p>
        <p>
         Levels of factors II, VII, IX, and X are reduced to approximately 20 to 60 percent of normal, as reflected by prolongation of the PT and aPTT [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p>
         The disorder can be fully corrected by supplementation with daily oral vitamin K in most patients [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
         VKDCFD types I and II can be distinguished by genetic testing and/or by accumulation of vitamin K epoxide after vitamin K supplementation in patients with VKDCFD type II [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3690619010">
         <span class="h3">
          Vascular disease associated with VKORC1 variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Variants in
         <em>
          VKORC1
         </em>
         may also be associated with increased risk for arterial vascular disease [
         <a href="#rid140">
          140
         </a>
         ]. Missense mutation of
         <em>
          VKORC1
         </em>
         coupled with limited vitamin K ingestion in rats leads to areas of massive vascular calcification associated with increased expression of uncarboxylated matrix Gla protein [
         <a href="#rid141">
          141
         </a>
         ]. Similar observations were made in mice deficient in matrix Gla protein [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3763932751">
         <span class="h3">
          Hereditary warfarin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Missense mutations in
         <em>
          VKORC1
         </em>
         have been proposed to be involved in resistance to
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and other vitamin K antagonist (VKA) anticoagulants [
         <a href="#rid18">
          18,142-145
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         resistance maps to variants in two regions of the VKOR enzyme and to the
         <em>
          VKORC1
         </em>
         promotor [
         <a href="#rid18">
          18,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quinone binding pocket
         </strong>
         – This is the region where Asn80 and Tyr139 (the commonly mutated residue that confers rodenticide resistance in rats) form hydrogen bonds with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cap
         </strong>
         – The cap that seals the quinone/VKA binding site (or residues interacting with the cap) are sites of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         binding. The cap contains a pair of conserved cysteines (C43 and C51). (See
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Promotor
         </strong>
         – Common variants within the
         <em>
          VKORC1
         </em>
         gene such as the promotor polymorphism -1639G&gt;A influence VKOR expression and the mean daily dose of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         required to acquire target anticoagulation intensity [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite the role of genotype in
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         sensitivity, randomized trials that evaluated genotyping to determine the initial dosing of warfarin did not demonstrate improved outcomes with genotype-guided dosing [
         <a href="#rid147">
          147
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects", section on 'Baseline testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Warfarin and VKORC1 polymorphisms'
         </a>
         .)
        </p>
        <p>
         Factors that affect
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         dosing are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin resistance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1948199955">
         <span class="h2">
          Poisoning by rodenticide superwarfarins
         </span>
         <span class="headingEndMark">
          —
         </span>
         An extreme case of VKA toxicity is poisoning by "superwarfarins"; these rodenticides are VKOR inhibitors that are two orders of magnitude more potent than
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and have half-lives measured in weeks. (See
         <a class="medical medical_review" href="/z/d/html/94398.html" rel="external">
          "Overview of rodenticide poisoning", section on 'Anticoagulants (superwarfarins and warfarins)'
         </a>
         .)
        </p>
        <p>
         Tight binding of superwarfarins to VKOR is enhanced by insertion of bulky substituents into the hydrophobic groove otherwise occupied by the long isoprenoid tail of vitamin K [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Treatment with high doses of vitamin K quinone for several months or years is often required to reverse the coagulopathy associated with superwarfarin poisoning [
         <a href="#rid148">
          148
         </a>
         ]. The exact dose of vitamin K required must be determined empirically and titrated to ensure a normal prothrombin time (PT); in most cases of poisoning by the superwarfarin brodifacoum, typical total daily doses of vitamin K can range from 25 mg to 100 mg [
         <a href="#rid149">
          149
         </a>
         ]. This likely bypasses VKOR via FSP1 to ensure availability of the
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         KH2. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Superwarfarin poisoning'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26625679">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functions of Gla
         </strong>
         – In the presence of calcium ions, the amino acid gamma-carboxyglutamic acid (Gla) in Gla domains undergo a conformational change that exposes a phospholipid binding site and allows binding to membrane phosphatidylserine. The resulting membrane localization is essential to the function of vitamin K-dependent clotting proteins and natural anticoagulants. Gla-containing proteins in mineralized tissue may contribute to bone remodeling and may prevent calcification of extraosseous tissues by a less-well understood mechanism. Functions of Gla in other proteins is unclear. (See
         <a class="local">
          'Functions of Gla'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Clotting cascade and propagation of the clot'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Control mechanisms and termination of clotting'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conversion of Glu to Gla
         </strong>
         – The amino acid glutamate (Glu, also called glutamic acid) is converted to gamma-carboxyglutamic acid by a vitamin K-dependent carboxylase enzyme. Substrates include vitamin K-dependent clotting factors (II [prothrombin], VII, IX, and X), natural anticoagulants (proteins C, S, and Z), bone and matrix proteins, and other proteins of unknown function. (See
         <a class="local">
          'Gla synthesis'
         </a>
         above and
         <a class="local">
          'Protein substrates for gamma-carboxylation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Carboxylase
         </strong>
         – The carboxylase is an integral membrane protein. Cofactors include carbon dioxide, molecular oxygen, and the
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         form of vitamin K  (
         <a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Gamma-carboxylation recognition site'
         </a>
         above and
         <a class="local">
          'Gamma-glutamyl carboxylase enzyme'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vitamin K
         </strong>
         – For each molecule of Gla generated, one molecule of vitamin K is oxidized to vitamin K epoxide. Vitamin K epoxide reductase (VKOR) reduces vitamin K epoxide to vitamin K quinone (intermediate form) and vitamin K
         <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">
          hydroquinone
         </a>
         (KH2, the most reduced form and active cofactor for GGCX). (See
         <a class="local">
          'Vitamin K requirement'
         </a>
         above and
         <a class="local">
          'Vitamin K recycling by VKOR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Dietary vitamin K requirement and food sources are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2624.html" rel="external">
          "Overview of vitamin K"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          VKAs
         </strong>
         – Vitamin K antagonists (VKAs) such as
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         inhibit VKOR, resulting in dysfunctional vitamin K-dependent clotting proteins. FSP1 is a warfarin-independent vitamin K reductase that enables generation of sufficient amounts of reduced vitamin K with administration of excess vitamin K to act as an antidote for overdose of warfarin and other VKAs. FSP1 also protects against ferroptosis. (See
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control", section on 'Mechanism of action'
         </a>
         and
         <a class="local">
          'Ferroptosis suppressor 1 (FSP1) and other enzymes that can reduce vitamin K'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical implications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vitamin K-dependent clotting factor deficiency
         </strong>
         – Genetic deficiency of vitamin K-dependent clotting factors can be caused by pathogenic variants in genes that encode the gamma glutamyl carboxylase (
         <em>
          GGCX
         </em>
         gene) or the vitamin K recycling enzyme (
         <em>
          VKORC1
         </em>
         gene). (See
         <a class="local">
          'Genetic deficiency of GGCX (vitamin K-dependent clotting factor deficiency type I)'
         </a>
         above and
         <a class="local">
          'Genetic deficiency of VKOR (vitamin K-dependent clotting factor deficiency type II)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vascular calcification
         </strong>
         – Some
         <em>
          GGCX
         </em>
         and
         <em>
          VKORC1
         </em>
         variants can also cause aberrant calcification and other vascular abnormalities. (See
         <a class="local">
          'Syndromes with aberrant calcification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          VKA resistance or overdose
         </strong>
         – Some
         <em>
          VKORC1
         </em>
         variants cause resistance to vitamin K antagonists. Poisoning by superwarfarins used in rat poison may require prolonged vitamin K administration. (See
         <a class="local">
          'Hereditary warfarin resistance'
         </a>
         above and
         <a class="local">
          'Poisoning by rodenticide superwarfarins'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/94398.html" rel="external">
          "Overview of rodenticide poisoning", section on 'Anticoagulants (superwarfarins and warfarins)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1240993290">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Bruce Furie, MD, Beth A Bouchard, MD, and Barbara C Furie, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Roderick LM. A problem in the coagulation of the blood "sweet clover" disease of cattle. Am J Physiol 1931; 96:413.
          </a>
         </li>
         <li class="breakAll">
          The Antihæmorrhagic Vitamin of the Chick.: Occurrence And Chemical Nature. Nature 1935. 652. https://www.nature.com/articles/135652b0 (Accessed on December 28, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiura I, Furie B, Walsh CT, Furie BC. Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state. Proc Natl Acad Sci U S A 1997; 94:9069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowd P, Hershline R, Ham SW, Naganathan S. Vitamin K and energy transduction: a base strength amplification mechanism. Science 1995; 269:1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974; 71:2730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249:6347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmon CT, Sadowski JA, Suttie JW. A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3- into prothrombin. J Biol Chem 1975; 250:4744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sperling R, Furie BC, Blumenstein M, et al. Metal binding properties of gamma-carboxyglutamic acid. Implications for the vitamin K-dependent blood coagulation proteins. J Biol Chem 1978; 253:3898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu SM, Cheung WF, Frazier D, Stafford DW. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science 1991; 254:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci U S A 1991; 88:2236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie BC, Ratcliffe JV, Tward J, et al. The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera. J Biol Chem 1997; 272:28258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A 1982; 79:6461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehemtulla A, Roth DA, Wasley LC, et al. In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1993; 90:4611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31:2554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermeer C, De Boer-Van den Berg MA. Vitamin K-dependent carboxylase. Haematologia (Budap) 1985; 18:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Li S, Shen G, et al. Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation. Science 2021; 371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Wang B, Li W, Rapoport TA. Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci U S A 2010; 107:15027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin DY, Chen X, Liu Y, et al. A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase. Nat Commun 2023; 14:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishima E, Ito J, Wu Z, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature 2022; 608:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A 1998; 95:9250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96:3049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van de Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezaie AR, Bae JS, Manithody C, et al. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem 2008; 283:19922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broze GJ Jr. Protein-Z and thrombosis. Lancet 2001; 357:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gris JC, Amadio C, Mercier E, et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101:4850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corral J, González-Conejero R, Hernández-Espinosa D, Vicente V. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007; 137:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Tu Y, Lu L, et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 2008; 111:4973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sofi F, Cesari F, Abbate R, et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 2010; 103:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard TJ, Lasky NM, Grunz K, Broze GJ Jr. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A. J Thromb Haemost 2019; 17:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard RA, Furie BC, Kruger SF, et al. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratcliffe JV, Furie B, Furie BC. The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis. J Biol Chem 1993; 268:24339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Jhingan A, Castellino FJ. Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Castellino FJ. The contributions of individual gamma-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles. J Biol Chem 1993; 268:12040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jhingan A, Zhang L, Christiansen WT, Castellino FJ. The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma. Biochemistry 1994; 33:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279:14338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shikamoto Y, Morita T, Fujimoto Z, Mizuno H. Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein. J Biol Chem 2003; 278:24090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin ZF, Huang ZF, Cui J, et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 2000; 97:6734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang M, Rigby AC, Morelli X, et al. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 2003; 10:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen WT, Jalbert LR, Robertson RM, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles. Biochemistry 1995; 34:10376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunnerhagen M, Forsén S, Hoffrén AM, et al. Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol 1995; 2:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald JF, Shah AM, Schwalbe RA, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36:5120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez Y, Mezei M, Osman R. The PT1-Ca2+ Gla domain binds to a membrane through two dipalmitoylphosphatidylserines. A computational study. Biochemistry 2008; 47:13267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7:e43229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munroe PB, Olgunturk RO, Fryns JP, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999; 21:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao Y, Shahbazian A, Boström KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res 2008; 102:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schurgers LJ, Spronk HM, Skepper JN, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007; 5:2503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viegas CS, Simes DC, Laizé V, et al. Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem 2008; 283:36655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13:4976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano T, Kawamoto K, Kishino J, et al. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323 ( Pt 2):387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulman JD, Harris JE, Haldeman BA, Davie EW. Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc Natl Acad Sci U S A 1997; 94:9058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulman JD, Harris JE, Xie L, Davie EW. Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc Natl Acad Sci U S A 2001; 98:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu S, Han JC, Morales A, et al. Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res 2008; 122:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacombe J, Guo K, Bonneau J, et al. Vitamin K-dependent carboxylation regulates Ca2+ flux and adaptation to metabolic stress in β cells. Cell Rep 2023; 42:112500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price PA, Williamson MK. Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate. Protein Sci 1993; 2:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkner KL, Pudota BN. Vitamin K-dependent carboxylation of the carboxylase. Proc Natl Acad Sci U S A 1998; 95:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh JM, Olivera BM, Cruz LJ, Gray WR. Gamma-carboxyglutamate in a neuroactive toxin. J Biol Chem 1984; 259:14343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigby AC, Lucas-Meunier E, Kalume DE, et al. A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca2+ influx. Proc Natl Acad Sci U S A 1999; 96:5758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan Y, Balsara RD, Zajicek J, et al. Discerning the Role of the Hydroxyproline Residue in the Structure of Conantokin Rl-B and Its Role in GluN2B Subunit-Selective Antagonistic Activity toward N-Methyl-d-Aspartate Receptors. Biochemistry 2016; 55:7112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itang CEMM, Gaza JT, Masacupan DJM, et al. Identification of Conomarphin Variants in the Conus eburneus Venom and the Effect of Sequence and PTM Variations on Conomarphin Conformations. Mar Drugs 2020; 18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knobloch JE, Suttie JW. Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X. J Biol Chem 1987; 262:15334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Furie BC, Furie B, Walsh CT. The propeptide of the vitamin K-dependent carboxylase substrate accelerates formation of the gamma-glutamyl carbanion intermediate. Biochemistry 1997; 36:6384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price PA, Fraser JD, Metz-Virca G. Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. Proc Natl Acad Sci U S A 1987; 84:8335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hao Z, Jin DY, Stafford DW, Tie JK. Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study. Haematologica 2020; 105:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard BR, Ulrich MM, Jacobs M, et al. Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. Proc Natl Acad Sci U S A 1989; 86:6893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tward JD, Furie BC, Bouchard BA, et al. Other amino acids than phenylalanine at position 16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation. Blood 1997; 90(Suppl 1):291a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huber P, Schmitz T, Griffin J, et al. Identification of amino acids in the gamma-carboxylation recognition site on the propeptide of prothrombin. J Biol Chem 1990; 265:12467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldenburg J, Kriz K, Wuillemin WA, et al. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 2001; 85:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristensen SR. Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. Blood 2002; 100:2676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dissing C, Persson E. Factor VII Tokushima (Cys22→Gly) is not γ-carboxylated due to a disrupted γ-carboxylase recognition site. Thromb Res 2017; 158:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presnell SR, Stafford DW. The vitamin K-dependent carboxylase. Thromb Haemost 2002; 87:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris DP, Soute BA, Vermeer C, Stafford DW. Characterization of the purified vitamin K-dependent gamma-glutamyl carboxylase. J Biol Chem 1993; 268:8735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuliopulos A, Hubbard BR, Lam Z, et al. Dioxygen transfer during vitamin K dependent carboxylase catalysis. Biochemistry 1992; 31:7722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin PJ, Jin DY, Tie JK, et al. The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site. J Biol Chem 2002; 277:28584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutucumarana VP, Acher F, Straight DL, et al. A conserved region of human vitamin K-dependent carboxylase between residues 393 and 404 is important for its interaction with the glutamate substrate. J Biol Chem 2003; 278:46488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo WL, Stafford DW, Cruces J, et al. Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12. Genomics 1995; 25:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bristol JA, Ratcliffe JV, Roth DA, et al. Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of gamma-carboxylation. Blood 1996; 88:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268:8458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman PA, Shia MA, Gallop PM, Griep AE. Vitamin K-dependent gamma-carbon-hydrogen bond cleavage and nonmandatory concurrent carboxylation of peptide-bound glutamic acid residues. Proc Natl Acad Sci U S A 1979; 76:3126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood GM, Suttie JW. Vitamin K-dependent carboxylase. Stoichiometry of vitamin K epoxide formation, gamma-carboxyglutamyl formation, and gamma-glutamyl-3H cleavage. J Biol Chem 1988; 263:3234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack DO, Suen ET, Girardot JM, et al. Soluble enzyme system for vitamin K-dependent carboxylation. J Biol Chem 1976; 251:3269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman PA, Shia M. Some characteristics of a vitamin K-dependent carboxylating system from rat liver microsomes. Biochem Biophys Res Commun 1976; 70:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttie JW, Lehrman SR, Geweke LO, et al. Vitamin K-dependent carboxylase: requirements for carboxylation of soluble peptide and substrate specificity. Biochem Biophys Res Commun 1979; 86:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canfield LM, Sinsky TA, Suttie JW. Vitamin K-dependent carboxylase: purification of the rat liver microsomal enzyme. Arch Biochem Biophys 1980; 202:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canfield LM. Vitamin K-dependent oxygenase/carboxylase; differential inactivation by sulfhydryl reagents. Biochem Biophys Res Commun 1987; 148:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchard BA, Furie B, Furie BC. Glutamyl substrate-induced exposure of a free cysteine residue in the vitamin K-dependent gamma-glutamyl carboxylase is critical for vitamin K epoxidation. Biochemistry 1999; 38:9517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tie J, Wu SM, Jin D, et al. A topological study of the human gamma-glutamyl carboxylase. Blood 2000; 96:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pudota BN, Miyagi M, Hallgren KW, et al. Identification of the vitamin K-dependent carboxylase active site: Cys-99 and Cys-450 are required for both epoxidation and carboxylation. Proc Natl Acad Sci U S A 2000; 97:13033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandyopadhyay PK, Garrett JE, Shetty RP, et al. gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates. Proc Natl Acad Sci U S A 2002; 99:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tie JK, Mutucumarana VP, Straight DL, et al. Determination of disulfide bond assignment of human vitamin K-dependent gamma-glutamyl carboxylase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Biol Chem 2003; 278:45468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rishavy MA, Pudota BN, Hallgren KW, et al. A new model for vitamin K-dependent carboxylation: the catalytic base that deprotonates vitamin K hydroquinone is not Cys but an activated amine. Proc Natl Acad Sci U S A 2004; 101:13732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tie JK, Jin DY, Loiselle DR, et al. Chemical modification of cysteine residues is a misleading indicator of their status as active site residues in the vitamin K-dependent gamma-glutamyl carboxylation reaction. J Biol Chem 2004; 279:54079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen G, Cui W, Cao Q, et al. The catalytic mechanism of vitamin K epoxide reduction in a cellular environment. J Biol Chem 2021; 296:100145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem 1985; 54:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J 1987; 241:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spohn G, Kleinridders A, Wunderlich FT, et al. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb Haemost 2009; 101:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004; 29:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li W, Schulman S, Dutton RJ, et al. Structure of a bacterial homologue of vitamin K epoxide reductase. Nature 2010; 463:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JJ, Fasco MJ. Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide. Biochemistry 1984; 23:2246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Liu S, Liu XR, et al. Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy. Blood Adv 2020; 4:2202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutton RJ, Boyd D, Berkmen M, Beckwith J. Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation. Proc Natl Acad Sci U S A 2008; 105:11933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkevich LA, Williams DB. Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulum. Mol Biol Cell 2012; 23:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wajih N, Hutson SM, Wallin R. Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. J Biol Chem 2007; 282:2626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen G, Cui W, Zhang H, et al. Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. Nat Struct Mol Biol 2017; 24:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park BK, Choonara IA, Haynes BP, et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol 1986; 21:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988; 25:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamali F, Edwards C, Butler TJ, Wynne HA. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thromb Haemost 2000; 84:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjornsson TD, Blaschke TF. Vitamin K1 disposition and therapy of warfarin overdose. Lancet 1978; 2:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallin R, Gebhardt O, Prydz H. NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction. Biochem J 1978; 169:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingram BO, Turbyfill JL, Bledsoe PJ, et al. Assessment of the contribution of NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice. Biochem J 2013; 456:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner B, Sánchez-Vega B, Wu SM, et al. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998; 92:4554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spronk HM, Farah RA, Buchanan GR, et al. Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000; 96:3650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rost S, Fregin A, Koch D, et al. Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004; 126:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soute BA, Ulrich MM, Watson AD, et al. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost 1992; 68:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu A, Sun H, Raymond RM Jr, et al. Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase. Blood 2007; 109:5270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner B. Hereditary deficiency of vitamin K-dependent coagulation factors. Thromb Haemost 2000; 84:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousallem M, Spronk HM, Sacy R, et al. Congenital combined deficiencies of all vitamin K-dependent coagulation factors. Thromb Haemost 2001; 86:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soute BA, Jin DY, Spronk HM, et al. Characteristics of recombinant W501S mutated human gamma-glutamyl carboxylase. J Thromb Haemost 2004; 2:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Schurgers LJ, Smith AC, et al. Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene. Am J Pathol 2009; 174:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanakker OM, Martin L, Gheduzzi D, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 2007; 127:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tie JK, Carneiro JD, Jin DY, et al. Characterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disorders. Blood 2016; 127:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Grange DK, Armstrong NL, et al. Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes. J Invest Dermatol 2009; 129:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchetti G, Caruso P, Lunghi B, et al. Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 2008; 6:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldenburg J, von Brederlow B, Fregin A, et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. Am J Hum Genet 1987; 41:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czogalla KJ, Biswas A, Rost S, et al. The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif. Blood 2014; 124:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fregin A, Rost S, Wolz W, et al. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood 2002; 100:3229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaux A, Matagrin B, Debaux JV, et al. Missense mutation of VKORC1 leads to medial arterial calcification in rats. Sci Rep 2018; 8:13733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodin L, Horellou MH, Flaujac C, et al. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005; 3:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109:2477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilms EB, Touw DJ, Conemans JM, et al. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost 2008; 6:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peoc'h K, Pruvot S, Gourmel C, et al. A new VKORC1 mutation leading to an isolated resistance to fluindione. Br J Haematol 2009; 145:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 2013; 369:2345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Furie B. How I treat poisoning with vitamin K antagonists. Blood 2015; 125:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76:2555.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1318 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A problem in the coagulation of the blood "sweet clover" disease of cattle
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A problem in the coagulation of the blood "sweet clover" disease of cattle
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Studies on the hemorrhagic sweet clover disease IV. The isolation and crystallization of the hemorrhagic agent
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256436" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7569894" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Vitamin K and energy transduction: a base strength amplification mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4528109" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Vitamin K dependent modifications of glutamic acid residues in prothrombin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4214105" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1141226" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3- into prothrombin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25895" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Metal binding properties of gamma-carboxyglutamic acid. Implications for the vitamin K-dependent blood coagulation proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1749935" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cloning and expression of the cDNA for human gamma-glutamyl carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2006163" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Identification and purification to near homogeneity of the vitamin K-dependent carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3802193" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9353278" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6959130" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Isolation and characterization of a cDNA coding for human factor IX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8506307" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1547238" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3896983" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Vitamin K-dependent carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14765194" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14765195" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identification of the gene for vitamin K epoxide reductase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33154105" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696932" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36788244" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35922516" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A non-canonical vitamin K cycle is a potent ferroptosis suppressor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9689066" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Isolation of a protein Z-dependent plasma protease inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11049983" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Characterization of the protein Z-dependent protease inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15461625" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502758" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11289341" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Protein-Z and thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11487045" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Protein Z-dependent regulation of coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12623836" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anti-protein Z antibodies in women with pathologic pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391489" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344422" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20076855" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30451376" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6822761" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Immunoassays of human prothrombin species which correlate with functional coagulant activities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8226983" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1498334" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8505327" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The contributions of individual gamma-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8110790" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14722079" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12695512" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598903" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10829076" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prothrombotic phenotype of protein Z deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12923575" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7654691" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664114" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8663165" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9136872" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19086158" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The PT1-Ca2+ Gla domain binds to a membrane through two dipalmitoylphosphatidylserines. A computational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684484" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Increased bone formation in osteocalcin-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052783" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743228" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22952653" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9916809" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18369157" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848178" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18836183" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8336730" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9163328" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256434" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171957" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19096215" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37171959" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Vitamin K-dependent carboxylation regulates Ca2+ flux and adaptation to metabolic stress inβcells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8268808" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9435215" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Vitamin K-dependent carboxylation of the carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6501296" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Gamma-carboxyglutamate in a neuroactive toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10318957" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca2+ influx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27981829" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Discerning the Role of the Hydroxyproline Residue in the Structure of Conantokin Rl-B and Its Role in GluN2B Subunit-Selective Antagonistic Activity toward N-Methyl-d-Aspartate Receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33019526" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Identification of Conomarphin Variants in the Conus eburneus Venom and the Effect of Sequence and PTM Variations on Conomarphin Conformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2890628" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9174354" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The propeptide of the vitamin K-dependent carboxylase substrate accelerates formation of the gamma-glutamyl carbanion intermediate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3317405" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31624106" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2780546" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Other amino acids than phenylalanine at position 16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2373701" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Identification of amino acids in the gamma-carboxylation recognition site on the propeptide of prothrombin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8833911" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9233593" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11307814" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12360981" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28886472" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Factor VII Tokushima (Cys22→Gly) is notγ-carboxylated due to a disruptedγ-carboxylase recognition site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12083499" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The vitamin K-dependent carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8473318" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Characterization of the purified vitamin K-dependent gamma-glutamyl carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1510957" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Dioxygen transfer during vitamin K dependent carboxylase catalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12034728" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12968027" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A conserved region of human vitamin K-dependent carboxylase between residues 393 and 404 is important for its interaction with the glutamate substrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7759116" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8839851" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of gamma-carboxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8473289" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/290992" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Vitamin K-dependent gamma-carbon-hydrogen bond cleavage and nonmandatory concurrent carboxylation of peptide-bound glutamic acid residues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2830277" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Vitamin K-dependent carboxylase. Stoichiometry of vitamin K epoxide formation, gamma-carboxyglutamyl formation, and gamma-glutamyl-3H cleavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6448" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Soluble enzyme system for vitamin K-dependent carboxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/938518" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Some characteristics of a vitamin K-dependent carboxylating system from rat liver microsomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/426799" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Vitamin K-dependent carboxylase: requirements for carboxylation of soluble peptide and substrate specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7458333" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Vitamin K-dependent carboxylase: purification of the rat liver microsomal enzyme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3675572" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Vitamin K-dependent oxygenase/carboxylase; differential inactivation by sulfhydryl reagents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10413529" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Glutamyl substrate-induced exposure of a free cysteine residue in the vitamin K-dependent gamma-glutamyl carboxylase is critical for vitamin K epoxidation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910912" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A topological study of the human gamma-glutamyl carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11087858" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Identification of the vitamin K-dependent carboxylase active site: Cys-99 and Cys-450 are required for both epoxidation and carboxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11818531" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963724" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Determination of disulfide bond assignment of human vitamin K-dependent gamma-glutamyl carboxylase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365175" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A new model for vitamin K-dependent carboxylation: the catalytic base that deprotonates vitamin K hydroquinone is not Cys but an activated amine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492002" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Chemical modification of cysteine residues is a misleading indicator of their status as active site residues in the vitamin K-dependent gamma-glutamyl carboxylation reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33273012" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The catalytic mechanism of vitamin K epoxide reduction in a cellular environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3896125" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Vitamin K-dependent carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3593198" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19492146" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15276181" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Vitamin K epoxide reductase: homology, active site and catalytic mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20110994" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Structure of a bacterial homologue of vitamin K epoxide reductase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6733086" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32433747" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18695247" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496424" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17124179" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27918545" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3964529" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3370190" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260056" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The association of vitamin K status with warfarin sensitivity at the onset of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10928467" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/81403" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Vitamin K1 disposition and therapy of warfarin overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/629756" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24015818" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Assessment of the contribution of NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9845520" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11071668" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15287948" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1455398" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327402" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11154137" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Hereditary deficiency of vitamin K-dependent coagulation factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11816728" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Congenital combined deficiencies of all vitamin K-dependent coagulation factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15102014" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Characteristics of recombinant W501S mutated human gamma-glutamyl carboxylase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19116367" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110937" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758921" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Characterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18800149" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18315553" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11154138" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3499071" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24963046" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384421" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549638" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30214074" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Missense mutation of VKORC1 leads to medial arterial calcification in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15978113" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110455" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18419745" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19344422" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : A new VKORC1 mutation leading to an isolated resistance to fluindione.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15930419" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24251364" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25377783" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : How I treat poisoning with vitamin K antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2265249" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
